MX2022000892A - Metodos para tratar trastornos del sue?o asociados con el dolor. - Google Patents

Metodos para tratar trastornos del sue?o asociados con el dolor.

Info

Publication number
MX2022000892A
MX2022000892A MX2022000892A MX2022000892A MX2022000892A MX 2022000892 A MX2022000892 A MX 2022000892A MX 2022000892 A MX2022000892 A MX 2022000892A MX 2022000892 A MX2022000892 A MX 2022000892A MX 2022000892 A MX2022000892 A MX 2022000892A
Authority
MX
Mexico
Prior art keywords
pain
patient
sleep disorder
methods
sleep
Prior art date
Application number
MX2022000892A
Other languages
English (en)
Spanish (es)
Inventor
Michael Smith
Paul Blahunka
Gerard Marek
Katherine Tracy
Mary Beth Blauwet
Mark Walzer
Marci English
Original Assignee
Astellas Pharma Global Dev Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Global Dev Inc filed Critical Astellas Pharma Global Dev Inc
Publication of MX2022000892A publication Critical patent/MX2022000892A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2022000892A 2019-07-23 2020-07-22 Metodos para tratar trastornos del sue?o asociados con el dolor. MX2022000892A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962877573P 2019-07-23 2019-07-23
PCT/US2020/043047 WO2021016338A1 (en) 2019-07-23 2020-07-22 Methods of treating sleep disorders associated with pain

Publications (1)

Publication Number Publication Date
MX2022000892A true MX2022000892A (es) 2022-03-11

Family

ID=72047043

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000892A MX2022000892A (es) 2019-07-23 2020-07-22 Metodos para tratar trastornos del sue?o asociados con el dolor.

Country Status (10)

Country Link
US (1) US20220370468A1 (https=)
EP (1) EP4003357A1 (https=)
JP (1) JP2022541634A (https=)
KR (1) KR20220038344A (https=)
CN (1) CN114144183A (https=)
AU (1) AU2020318996A1 (https=)
BR (1) BR112022001056A2 (https=)
CA (1) CA3147752A1 (https=)
MX (1) MX2022000892A (https=)
WO (1) WO2021016338A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320637D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
MX350745B (es) * 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
SG11201509989VA (en) * 2013-06-06 2016-01-28 Astellas Pharma Inc Benzothiophene compound

Also Published As

Publication number Publication date
KR20220038344A (ko) 2022-03-28
BR112022001056A2 (pt) 2022-05-24
JP2022541634A (ja) 2022-09-26
AU2020318996A1 (en) 2022-02-03
CA3147752A1 (en) 2021-01-28
CN114144183A (zh) 2022-03-04
EP4003357A1 (en) 2022-06-01
WO2021016338A1 (en) 2021-01-28
US20220370468A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
EA201992046A1 (ru) Способ и система для управления стимуляцией головного мозга при помощи биодатчиков
EA201390827A1 (ru) Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом
EA202090043A1 (ru) Диазабициклические замещенные имидазопиримидины и их применение
SG176628A1 (en) Aminopyrrolidinone derivatives and uses thereof
EA201591290A3 (ru) Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3
HK1202776A1 (en) Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy
MY209349A (en) Methods of treating myeloproliferative disorders
EA200970764A1 (ru) Способ лечения расстройств, вызванных пролиферацией клеток, с применением стимуляторов секреции гормона роста
MX2022000892A (es) Metodos para tratar trastornos del sue?o asociados con el dolor.
WO2020084113A8 (en) Sildenafil for use in the treatment of osteoarthritis
ATE506941T1 (de) Behandlung psychiatrischer patienten mit schlafstörungen und/oder übermässiger tagesschläfrigkeit mit paliperidon
US20210299080A1 (en) Method of treatment
EP2724746B1 (en) System and method for scheduling light therapy
JOP20200046A1 (ar) طرق لعلاج أمراض مرتبطة بـtnf?
EP1622450A4 (en) PROCESS FOR PROMOTING UNINTERRUPTED SLEEP BY ADMINISTERING TROPIUM CHLORIDE
RU2020120236A (ru) Способы применения феноксипропиламиновых соединений для лечения депрессии
Scott Music and your body: How music affects us and why music therapy promotes health
BR112022000734A2 (pt) Método para tratar câncer em um paciente, uso de composto 1, e, composto 1
Honma et al. Sleep-wake cycles in Humans
RU2648957C1 (ru) Способ лечения эпилептических спазмов
RU2013137690A (ru) Способ лечения отсеохондропатии головки бедренной кости
Choi et al. 0779 Circadian Entrainment in 12h Night Shift Workers: The Environmental Lights Matter?
Sathe Hypnic jerks treated by clonazepam: case report
Zhang et al. 0778 Workplace Yoga Program Features and Associations With Shift Work and Sleep Among Nursing Staff
Walters 27 Opioids and the Restless Legs Syndrome: Treatment and Pathogenetic Considerations